Skip to main content
SpringerLink
Log in

Drugs for HIV-Related Opportunistic Infections

  • Chapter
Drug Interactions in Infectious Diseases

Part of the book series: Infectious Disease ((ID))

  • 781 Accesses

Abstract

As outlined in Chapter 5, drug interactions in human immunodeficiency virus (HIV) are encountered frequently, particularly with protease inhibitors and nonnucleoside reverse transcriptase inhibitors (NNRTIs). In a retrospective chart review of 165 HIV patients newly prescribed a protease inhibitor, at least one potential drug interaction was identified in 82 (49.7%) of the patients (1). In total, 111 interactions were identified, but only 22 (19.8%) were recognized at the time of protease inhibitor therapy initiation. An additional 12 drug interactions were later identified at follow-up, but 77 (69.3%) were never recognized. At the time this study was conducted, only three protease inhibitors (saquinavir, ritonavir, and indinavir) were available. More recently, in a chart review of 189 ambulatory HIV patients, 466 interactions were identified in 153 subjects for an average of 2.46 interactions per patient (2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Preston SL, Postelnick M, Purdy BD, Petrolati J, Aasi H, Stein DS. Drug interactions in HIV-positive patients initiated on protease inhibitor therapy [letter]. AIDS 1998;12:228–230.

    PubMed  CAS  Google Scholar 

  2. Mur Lalaguna MA, Cobo Campos R, Hurtado Gomez MF, Martinez Tutor MJ. [Study of interactions between anti-retroviral agents and concomitant drugs]. Farmacia Hospitalaria 2003;27:84–92.

    PubMed  CAS  Google Scholar 

  3. Palella FJJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853–860.

    PubMed  Google Scholar 

  4. Moore RD, Keruly JC, Chaisson RE. Decline in CMV and other opportunistic disease with combination antiretroviral therapy. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5, 1998, p. 113. Abstract 184.

    Google Scholar 

  5. Holtzer CD, Jacobson MA, Hadley WK, et al. Decline in the rate of specific opportunistic infections at San Francisco General Hospital, 1994–1997 [letter]. AIDS 1998;12:1931–1933.

    PubMed  CAS  Google Scholar 

  6. United States Public Health Services/ Infectious Diseases Society of America (USPHS/IDSA) Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. November 28, 2001. USPHS/IDSA, Washington, DC

    Google Scholar 

  7. Michelet C, Arvieux C, Francois C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998;12:1815–1822.

    PubMed  CAS  Google Scholar 

  8. Horowitz HW, Telzak EE, Sepkowitz KA, Wormser GP. Human immunodeficiency virus infection, Part II. Disease-A-Month 1998;44:677–716.

    PubMed  CAS  Google Scholar 

  9. Abbott Laboratories Limited Canada. Norvir (ritonavir) prescribing information. Saint-Laurent, QC: 2001.

    Google Scholar 

  10. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995;333:1662–1669.

    PubMed  CAS  Google Scholar 

  11. Veal GJ, Hoggard PG, Barry MG, Khoo S, Back DJ. Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation [letter]. AIDS 1996;10:546–548.

    PubMed  CAS  Google Scholar 

  12. Back D, Haworth S, Hoggard P, Khoo S, Barry M. Drug interactions with d4T phosphorylation in vitro [abstract]. Eleventh International Conference on AIDS, Vancouver, Canada, July 1996.

    Google Scholar 

  13. Fletcher CV, Anderson PL, Kakuda TN, et al. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 2002;16:551–560.

    PubMed  Google Scholar 

  14. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. Indinavir concentrations and antiviral effect. Pharmacotherapy 1999;19:708–712.

    PubMed  CAS  Google Scholar 

  15. Harris M, Durakovic C, Rae S, et al. Virologic response to indinavir/nevirapine/3TC correlates with indinavir trough concentrations. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997. Abstract I-173.

    Google Scholar 

  16. Hertogs K, Mellors JW, Schel P, et al. Patterns of cross-resistance among protease inhibitors in 483 clinical HIV-1 isolates. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5, 1998. Abstract 395.

    Google Scholar 

  17. Patick AK, Mo H, Markowitz M, et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996;40:292–297.

    PubMed  CAS  Google Scholar 

  18. Sampson MS, Barr MR, Torres RA, Hall G. Viral load changes in nelfinavir treated patients switched to a second protease inhibitor after loss of viral suppression. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997. Abstract LB-5.

    Google Scholar 

  19. Deeks S, Grant R, Horton C, Simmonds N, Follansbee S, Eastman S. Virologic effect of ritonavir plus saquinavir in subjects who have failed indinavir. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997. Abstract I-205.

    Google Scholar 

  20. Sampson M, Torres RA, Stein AJ, et al. Ritonavir-saquinavir combination treatment in protease inhibitor experienced patients with advanced HIV disease. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997. Abstract I-104.

    Google Scholar 

  21. Woolley J, Studenberg S, Boehlert C, Bowers G, Sinhababu A, Adams P. Cytochrome P-450 isozyme induction, inhibition, and metabolism studies with the HIV protease inhibitor, 141W94. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997. Abstract A-60.

    Google Scholar 

  22. Yeh KC, Deutsch PJ, Haddix H, et al. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 1998;42:332–338.

    PubMed  CAS  Google Scholar 

  23. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190–194.

    PubMed  CAS  Google Scholar 

  24. Lee CA, Liang BH, Wu EY, et al. Prediction of nelfinavir mesylate (VIRACEPT) clinical drug interactions based on in vitro human P450 metabolism studies. Fourth National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22–26, 1997.

    Google Scholar 

  25. Agouron Pharmaceuticals Canada. Rescriptor (delavirdine) prescribing information. Mississauga, Ontario, Canada, 2001

    Google Scholar 

  26. Boehringer Ingelheim Pharmaceuticals. Viramune (nevirapine) product monograph. Ridgefield, CT, September 4, 2003.

    Google Scholar 

  27. Bristol-Myers Squibb Company. Sustiva (efavirenz) prescribing information. Princeton, NJ, 2003.

    Google Scholar 

  28. Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother 1999;33:461–473.

    PubMed  CAS  Google Scholar 

  29. Tseng AL, Foisy MM. Management of drug interactions in patients with HIV. Ann Pharmacother 1997;31:1040–1058.

    PubMed  CAS  Google Scholar 

  30. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions in patients infected with HIV. Clin Infect Dis 1996;23:685–693.

    PubMed  CAS  Google Scholar 

  31. Metroka CE, McMechan MR, Andrada R, Laubenstein LJ, Jacobus DP. Failure of prophylaxis with dapsone in patients taking dideoxyinosine [letter]. N Engl J Med 1991;325:737.

    PubMed  CAS  Google Scholar 

  32. Sahai J, Garber G, Gallicano K, Oliveras L, Cameron DW. Effects of the antacids in didanosine tablets on dapsone pharmacokinetics. Ann Intern Med 1995;123:584–587.

    PubMed  CAS  Google Scholar 

  33. Bristol-Myers Squibb Company. Videx (didanosine) prescribing information. Princeton, NJ, February 2003.

    Google Scholar 

  34. Lee BL, Tauber MG, Sadler B, Goldstein D, Chambers HR. Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine. Clin Pharmacol Ther 1996;59:14–21.

    PubMed  CAS  Google Scholar 

  35. Sadler BM, Caldwell P, Scott JD, Rogers M, Blum MR. Drug interaction between rifampin and atovaquone in HIV+ asymptomatic volunteers [abstract]. Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17–20, 1995.

    Google Scholar 

  36. Moore KHP, Yuen GJ, Raasch RH, et al. Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole. Clin Pharmacol Ther 1996;59:550–558.

    PubMed  CAS  Google Scholar 

  37. Israelski DM, Tom C, Remington JS. Zidovudine antagonizes the action of pyrimethamine in experimental infection with Toxoplasma gondii. Antimicrob Agents Chemother 1989;33:30–34.

    PubMed  CAS  Google Scholar 

  38. Harvey WD, Holzman RS, Avramis V, Bawdon R, Fall H, Feinberg J. Clinical and pharmacokinetic interactions of combined zidovudine therapy and sulfadoxine-pyrimethamine (Fansidar) prophylaxis in post-PCP AIDS patients (ACTG 021). Fifth International Conference on AIDS, Montreal, June 1989. Abstract TBP 46.

    Google Scholar 

  39. Lee BL, Safrin S. Interactions and toxicities of drugs used in patients with AIDS. Clin Infect Dis 1992;14:773–779.

    PubMed  CAS  Google Scholar 

  40. Burger DM, Meenhorst PL, Koks CHW, Beijnen JH. Drug interactions with zidovudine. AIDS 1993;7:445–460.

    PubMed  CAS  Google Scholar 

  41. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway [editorial]. AIDS 1998;12:1735–1744.

    PubMed  CAS  Google Scholar 

  42. Kaufman MB, Simionatto C. A review of protease inhibitor-induced hyperglycemia. Pharmacotherapy 1999;19:114–117.

    PubMed  CAS  Google Scholar 

  43. Gordin FM, Simon GL, Wofsy CB, Mills J. Adverse reactions to trimethoprim-sulfamethoxazole in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1984;100:495–499.

    PubMed  CAS  Google Scholar 

  44. Foisy MM, Slayter KL, Hewitt RG, Morse GD. Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didanosine. Ann Pharmacother 1994;28:1025–1028.

    PubMed  CAS  Google Scholar 

  45. Darouiche RO. Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues. Clin Infect Dis 1998;26:259–274.

    PubMed  CAS  Google Scholar 

  46. Vasquez JA. Options for the management of mucosal candidiasis in patients with AIDS and HIV infection. Pharmacotherapy 1999;19:76–87.

    Google Scholar 

  47. Greenblatt RM, Hollander H, McMaster JR, et al. Polypharmacy among patients attending an AIDS clinic: utilization of prescribed, unorthodox, and investigational treatments. J Acquir Immune Defic Syndr 1991;4:136–143.

    PubMed  CAS  Google Scholar 

  48. Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998;32:915–928.

    PubMed  CAS  Google Scholar 

  49. Blum RA, D’Andrea DT, Florentino BM, et al. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991;114:755–757.

    PubMed  CAS  Google Scholar 

  50. Hardin TC, Sharkey-Mathis PK, Rinaldi MG, Graybill JR. Evaluation of the pharmacokinetic interaction between itraconazole and didanosine in HIV-infected subjects [abstract]. Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17–20, 1995.

    Google Scholar 

  51. Knupp CA, Brater C, Relue J, Barbhaiya RH. Pharmacokinetics of didanosine and ketoconazole after coadministration to patients seropositive for the human immunodeficiency virus. J Clin Pharmacol 1993;33:912–917.

    PubMed  CAS  Google Scholar 

  52. Moreno F, Hardin TC, Rinaldi MG, Graybill JR. Itraconazole-didanosine excipient interaction [letter]. JAMA 1993;269:1508.

    PubMed  CAS  Google Scholar 

  53. May DB, Drew RH, Yedinak KC, Bartlett JA. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 1994;14:509–513.

    PubMed  CAS  Google Scholar 

  54. Damle B, Hess H, Kaul S, Knupp C. Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. Biopharm Drug Dispos 2002;23:59–66.

    PubMed  CAS  Google Scholar 

  55. Damle BD, Mummaneni V, Kaul S, Knupp CA. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob Agents Chemother 2002;46:385–391.

    PubMed  CAS  Google Scholar 

  56. Sahai J. Avoiding the ciprofloxacin-didanosine interaction [letter]. Ann Intern Med 1995;123:394–395.

    PubMed  CAS  Google Scholar 

  57. Ervine CM, Matthew DE, Brennan B, Houston JB. Comparison of ketoconazole and fluconazole as cytochrome P450 inhibitors. Use of steady-state infusion approach to achieve plasma concentration-response relationships. Drug Metab Dispos 1996;24:211–215.

    PubMed  CAS  Google Scholar 

  58. Merck and Co. Crixivan (indinavir) prescribing information. Whitehouse Station, NJ, January 2003.

    Google Scholar 

  59. Back DJ, Gatti G, Fletcher C, et al. Therapeutic drug monitoring in HIV infection: current status and future directions. AIDS 2002;16:S5–S37.

    PubMed  CAS  Google Scholar 

  60. Lamson M, Robinson P, Gigliotti M, Myers M. The pharmacokinetic interactions of nevirapine and ketoconazole. Twelfth World AIDS Conference, Geneva, Switzerland, June 28–July 3, 1998. Abstract 12218.

    Google Scholar 

  61. Asgari M, Back DJ. Effect of azoles on the glucuronidation of zidovudine by human liver UDP-glucuronosyltransferase [letter; comment]. J Infect Dis 1995;172:1634–1636.

    PubMed  CAS  Google Scholar 

  62. Sampol E, Lacarelle B, Rajaonarison JF, Catalin J, Durand A. Comparative effects of antifungal agents on zidovudine glucuronidation by human liver microsomes. Br J Clin Pharmacol 1995;40:83–86.

    PubMed  CAS  Google Scholar 

  63. Sahai J, Gallicano K, Pakuts A, Cameron DW. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus [see comments]. J Infect Dis 1994;169:1103–1107.

    PubMed  CAS  Google Scholar 

  64. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:203–209.

    PubMed  CAS  Google Scholar 

  65. Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers [published erratum appears in Pharm Res 1998;15:958]. Pharm Res 1998;15:423–428.

    PubMed  CAS  Google Scholar 

  66. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;37:3594–3601.

    PubMed  CAS  Google Scholar 

  67. Kim AE, Dintaman JM, Waddell DS, Silverman JA. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998;286:1439–1445.

    PubMed  CAS  Google Scholar 

  68. Anderson PL, Lamba J, Schuetz E, Fletcher CV. MDR1 genotypes associated with antiviral dynamics and indinavir (IDV) disposition in HIV-infected patients. Fourth International Workshop on Clinical Pharmacology of HIV Therapy, Cannes, France, March 27–29, 2003. Abstract 2.1.

    Google Scholar 

  69. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. [comment]. Lancet 2002;359:30–36.

    PubMed  CAS  Google Scholar 

  70. Kim RB. Drug transporters in HIV therapy. Topics HIV Med 2003;11:136–139.

    Google Scholar 

  71. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289–294.

    PubMed  CAS  Google Scholar 

  72. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T. Interaction with Pglycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 1998;358:289–294.

    PubMed  CAS  Google Scholar 

  73. Khaliq Y, Gallicano K, Venance S, et al. Effect of the p-glycoprotein and cytochrome P450 3A4 inhibitor ketoconazole, on ritonavir and saquinavir plasma and cerebrospinal fluid concentrations. Eighth Annual Canadian Conference on HIV/AIDS Research, Victoria, British Columbia, Canada, May 1–4, 1999. Abstract B 205.

    Google Scholar 

  74. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Safety 1998;18:83–97.

    PubMed  CAS  Google Scholar 

  75. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997;337:15–21.

    PubMed  Google Scholar 

  76. Lewis RE, Lund BC, Klepser ME, Ernst EJ, Pfaller MA. Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrob Agents Chemother 1998;42:1382–1386.

    PubMed  CAS  Google Scholar 

  77. Ghannoum MA, Fu Y, Ibrahim AS, et al. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob Agents Chemother 1995;39:2459–2465.

    PubMed  CAS  Google Scholar 

  78. Scheven M, Schwegler F. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob Agents Chemother 1995;39:1779–1783.

    PubMed  CAS  Google Scholar 

  79. Scheven J, Scheven ML. Interaction between azoles and amphotericin B in the treatment of candidiasis [letter]. Clin Infect Dis 1995;20:1079.

    PubMed  CAS  Google Scholar 

  80. Clark AB, Lobo BL, Gelfand MS. Fluconazole and amphotericin B for cryptococcal meningitis. Ann Pharmacother 1996;30:1408–1410.

    PubMed  CAS  Google Scholar 

  81. Merck and Co. Cancidas (caspofungin) prescribing information. Whitehouse Station, NJ, September 2002.

    Google Scholar 

  82. Chin DP, DeRiemer K, Small PM, et al. Differences in contributing factors to tuberculosis incidence in U.S.-born and foreign-born persons. Am J Resp Crit Care Med 1998;158:1797–1803.

    PubMed  CAS  Google Scholar 

  83. Murray JF. Tuberculosis and HIV infection: a global perspective. Respiration 1998;65:335–342.

    PubMed  CAS  Google Scholar 

  84. Pilheu JA. Tuberculosis 2000: problems and solutions. Int J Tuberculosis Lung Dis 1998;2:696–703.

    CAS  Google Scholar 

  85. Snyder DC, Mohle-Boetani JC, Chandler A, Oliver G, Livermore T, Royce S. A population-based study determining the incidence of tuberculosis attributable to HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16:190–194.

    PubMed  CAS  Google Scholar 

  86. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47:1–58.

    Google Scholar 

  87. March F, Garriga X, Rodriguez P, et al. Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis. Clin Infect Dis 1997;25:1044–1047.

    PubMed  CAS  Google Scholar 

  88. Sahai J, Gallicano K, Swick L, et al. Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection. Ann Intern Med 1997;127:289–293.

    PubMed  CAS  Google Scholar 

  89. Peloquin CA, Nitta AT, Burman WJ, et al. Low antituberculosis drug concentrations in patients with AIDS. Ann Pharmacother 1996;30:919–925.

    PubMed  CAS  Google Scholar 

  90. Patel KB, Belmonte R, Crowe HM. Drug malabsorption and resistant tuberculosis in HIV-infected patients [letter]. N Engl J Med 1995;332:336–337.

    PubMed  CAS  Google Scholar 

  91. Burman WJ, Gallicano K, Peloquin C. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 1999;28:419–430.

    PubMed  CAS  Google Scholar 

  92. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210–258.

    PubMed  CAS  Google Scholar 

  93. de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW, Beijnen JH. Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet 2003;42:223–282.

    PubMed  Google Scholar 

  94. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Resp Crit Care Med 2001;164:7–12.

    PubMed  CAS  Google Scholar 

  95. Centers for Disease Control and Prevention. Treatment of tuberculosis. American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Morbid Mortal Wkly Rep 2003;52:1–88.

    Google Scholar 

  96. Centers for Disease Control and Prevention. Updated guidelines for the use of rifamycins for the treatment of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors [version 1.20.04]. MMWR Morbid Mortal Wkly Rep 2004;53:37.

    Google Scholar 

  97. Gallicano K, Khaliq Y, Carignan G, Tseng A, Walmsley S, Cameron DW. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2001;70:149–158.

    PubMed  CAS  Google Scholar 

  98. Borin MT, Chambers JH, Carel BJ, Gagnon S, Freimuth WW. Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate. Clin Pharmacol Ther 1997;61.

    Google Scholar 

  99. Borin MT, Chambers JH, Carel BJ, Freimuth WW, Aksentijevich S, Piergies AA. Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Res 1997;35:53–63.

    PubMed  CAS  Google Scholar 

  100. Cox SR, Herman BD, Batts DH, Carel BJ, Carberry PA. Delavirdine and rifabutin: pharmacokinetic evaluation in HIV-1 patients with concentration-targeting of delavirdine. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5, 1998. Abstract 344.

    Google Scholar 

  101. de Jong MD, Vella S, Carr A, et al. High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997;175:966–970.

    PubMed  Google Scholar 

  102. Cheeseman SH, Havlir D, McLaughlin MM, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr 1995;8:141–151.

    CAS  Google Scholar 

  103. Panel on Clinical Practices for Treatment of HIV Infection convened by the Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Federal Register, November 10, 2003.

    Google Scholar 

  104. Hilts AE, Fish DN. Dosage adjustment of antiretroviral agents in patients with organ dysfunction. Am J Health Syst Pharm 1998;55:2528–2533.

    PubMed  CAS  Google Scholar 

  105. Maserati R, Villani P, Seminari E, Pan A, Lo Caputo S, Regazzi MB. High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic disease. AIDS 1999;13:870–877.

    PubMed  CAS  Google Scholar 

  106. Tseng AL, Walmsley SL. Rifabutin-associated uveitis. Ann Pharmacother 1995;29:1149–1155.

    PubMed  CAS  Google Scholar 

  107. Davis JL, Taskintuna I, Freeman WR, Weinberg DV, Feuer WJ, Leonard RE. Iritis and hypotony after treatment with intravenous cidofovir for cytomegalovirus retinitis. Arch Ophthalmol 1997;115:733–737.

    PubMed  CAS  Google Scholar 

  108. Palau LA, Tufty GT, Pankey GA. Recurrent iritis after intravenous administration of cidofovir. Clin Infect Dis 1997;25:337–338.

    PubMed  CAS  Google Scholar 

  109. Tseng AL, Mortimer CB, Salit IE. Iritis associated with intravenous cidofovir. Ann Pharmacother 1999;33:167–171.

    PubMed  CAS  Google Scholar 

  110. Foulds G, Hilligoss DM, Henry EB, Gerber N. The effects of an antacid or cimetidine on the serum concentrations of azithromycin. J Clin Pharmacol 1991;31:164–167.

    PubMed  CAS  Google Scholar 

  111. Gillum JG, Bruzzese VL, Israel DS, Kaplowitz LG, Polk RE. Effect of clarithromycin on the pharmacokinetics of 2’,3’-dideoxyinosine in patients who are seropositive for human immunodeficiency virus. Clin Infect Dis 1996;22:716–718.

    PubMed  CAS  Google Scholar 

  112. Hafner R, Bethel J, Power M, et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 1998;42:631–639.

    PubMed  CAS  Google Scholar 

  113. Apseloff G, Foulds G, LaBoy-Goral L, Willavize S, Vincent J. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. J Clin Pharmacol 1998;38:830–835.

    PubMed  CAS  Google Scholar 

  114. Neuvonen PJ, Kivisto KT, Lehto P. Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther 1991;50:498–502.

    PubMed  CAS  Google Scholar 

  115. Polk RE, Healy DP, Sahai J, Drewal L, Racht E. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers. Antimicrob Agents Chemother 1989;33:1841–1844.

    PubMed  CAS  Google Scholar 

  116. Mueller BA, Abel SR, Brierton DG. Fluoroquinolone bioavailability in patients receiving nutritional supplements. Am J Health Syst Pharm 1995;52:892–893.

    PubMed  CAS  Google Scholar 

  117. Sahai J, Gallicano K, Oliveras L, Khaliq S, Hawley-Foss N, Garber G. Cations in the didanosine tablet reduce ciprofloxacin bioavailability. Clin Pharmacol Ther 1993;53:292–297.

    PubMed  CAS  Google Scholar 

  118. Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Nix DE. Effect of food and antacids on the pharmacokinetics of ethambutol and pyrazinamide. Thirty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28–October 1, 1997. Abstract A-3.

    Google Scholar 

  119. Mattila MJ, Linnoila M ST, Koskinen R. Effect of aluminium hydroxide and glycopyrrhonium on the absorption of ethambutol and alcohol in man. Br J Clin Pharmacol 1978;5:161–166.

    PubMed  CAS  Google Scholar 

  120. The Indinavir (MK 639) Pharmacokinetic Study Group. Indinavir (MK 639) drug interaction studies. Eleventh International Conference on AIDS, Vancouver, July 7–12, 1996, p. 18. Abstract Mo.B.174.

    Google Scholar 

  121. Snider DE Jr. Pyridoxine supplementation during isoniazid therapy. Tubercle 1980;61:191–196.

    PubMed  Google Scholar 

  122. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:153–161.

    PubMed  CAS  Google Scholar 

  123. Dalton K, Dalton MJ. Characteristics of pyridoxine overdose neuropathy syndrome. Acta Neurol Scand 1987;76:8–11.

    PubMed  CAS  Google Scholar 

  124. Snodgrass SR. Vitamin neurotoxicity. Mol Neurobiol 1992;6:41–73.

    PubMed  CAS  Google Scholar 

  125. Robinson P, Lamson M, Gigliotti M, Myers M. Pharmacokinetic interaction between nevirapine and rifampin. Twelfth World AIDS Conference, Geneva, Switzerland, June 28–July 3, 1998. Abstract 60623.

    Google Scholar 

  126. Taburet A, Singlas E. Drug interactions with antiviral drugs. Clin Pharmacokinet 1996;30:385–401.

    PubMed  CAS  Google Scholar 

  127. Pinching AJ, Helbert M, Peddle B, Robinson D, Janes K, Gor D. Clinical experience with zidovudine for patients with acquired immune deficiency syndrome and acquired immune deficiency syndrome-related complex. J Infect 1989;18(suppl 1):33–40.

    PubMed  Google Scholar 

  128. Hochster H, Dieterich D, Bozzette S, et al. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. Ann Intern Med 1990;113:111–117.

    PubMed  CAS  Google Scholar 

  129. Gaines K, Wong R, Jung D. Pharmacokinetic interactions with oral ganciclovir: zidovudine, didanosine, probenecid [abstract]. Tenth International Conference on AIDS, Yokohama, Japan, August 1994.

    Google Scholar 

  130. Hoffmann-LaRoche Limited. Cytovene (ganciclovir) prescribing information. Nutley, NJ, September 2000.

    Google Scholar 

  131. Morris DJ. Adverse effects and drug interactions of clinical importance with antiretrovirals. Drug Safety 1994;10:281–291.

    PubMed  CAS  Google Scholar 

  132. Millar AB, Miller RF, Patou G, Mindel A, Marsh R, Semple SJG. Treatment of cytomegalovirus retinitis with zidovudine and ganciclovir in patients with AIDS: outcome and toxicity. Genitourin Med 1990;66:156–158.

    PubMed  CAS  Google Scholar 

  133. Hermans P, Rozenbaum W, Jou A, et al. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. G-CSF 92105 Study Group. AIDS 1996;10:1627–1633.

    PubMed  CAS  Google Scholar 

  134. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213–220.

    Google Scholar 

  135. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med 1995;155:65–74.

    Google Scholar 

  136. Rockstroh JK. Management of hepatitis B and C in HIV co-infected patients. J Acquir Immune Defic Syndr 2003;34:S59–S65.

    PubMed  Google Scholar 

  137. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997;26:1–5.

    PubMed  CAS  Google Scholar 

  138. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIVinfected patients with chronic hepatitis C. Am J Gastroenterol 2001;96:179–183.

    PubMed  CAS  Google Scholar 

  139. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors’ Organisation. Lancet 1997;350:1425–1431.

    PubMed  CAS  Google Scholar 

  140. Lafeuillade A, Hittinger G, Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001;357:280–281.

    PubMed  CAS  Google Scholar 

  141. Salmon-Ceron D, Chauvelot-Moachon L, Abad S, Silbermann B, Sogni P. Mitochondrial toxic effects and ribavirin [comment]. Lancet 2001;357:1803–1804.

    PubMed  CAS  Google Scholar 

  142. Kakuda TN, Brinkman K. Mitochondrial toxic effects and ribavirin [comment]. Lancet 2001;357:1802–1803.

    PubMed  CAS  Google Scholar 

  143. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002;16:813–828.

    PubMed  Google Scholar 

  144. de Miranda P, Good SS, Yarchoan R, et al. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther 1989;46:494–500.

    PubMed  Google Scholar 

  145. Kornhauser DM, Petty BG, Hendrix CW, et al. Probenecid and zidovudine metabolism. Lancet 1989;2:473–475.

    PubMed  CAS  Google Scholar 

  146. Petty BG, Kornhauser DM, Lietman PS. Zidovudine with probenecid: a warning [letter]. Lancet 1990;335:1044–1045.

    PubMed  CAS  Google Scholar 

  147. Lalezari JP, Kuppermann BD. Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:S27–S31.

    PubMed  CAS  Google Scholar 

  148. Frascino RJ, Gaines Griffy K, Jung D, Yu S. Multiple dose crossover study of IV ganciclovir induction dose (5 mg/kg iv q 12 h) and didanosine (200 mg po q 12 h) in HIVinfected persons. Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17–20, 1995. Abstract A-27.

    Google Scholar 

  149. Bristol-Myers Squibb Co. Videx EC (didanosine enteric coated) prescribing information. Princeton, NJ, February 2003.

    Google Scholar 

  150. Hoffmann-LaRoche Laboratories. Valcyte (valganciclovir) prescribing information. Nutley, NJ, September 2003.

    Google Scholar 

  151. Glaxo Wellcome. Data on file, RM1996/00090/00. Personal communication, 1996.

    Google Scholar 

  152. Gallicano K, Sahai J, Swick L, Seguin I, Pakuts A, Cameron DW. Effect of rifabutin on the pharmacokinetics of zidovudine in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;21:1008–1011.

    PubMed  CAS  Google Scholar 

  153. Abbott Laboratories. Kaletra (lopinavir/ritonavir) prescribing information. North Chicago, IL: January 2003.

    Google Scholar 

  154. Falloon J, Lavelle J, Ogata-Arakaki D, et al. Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia. Antimicrob Agents Chemother 1994;38:1580–1587.

    PubMed  CAS  Google Scholar 

  155. McEvoy GK, ed. American Hospital Formulary Service Drug Information. Bethesda, MD: American Society of Health-System Pharmacists, 1995.

    Google Scholar 

  156. Zuidema J, Hilbers-Modderman ESM, Merkus FWHM. Clinical pharmacokinetics of dapsone. Clin Pharmacokinet 1986;11:299–315.

    PubMed  CAS  Google Scholar 

  157. Lee BL, Medina I, Benowitz NL, Jacob P, Wofsy CB, Mills J. Dapsone, trimethoprim and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with acquired immunodeficiency syndrome: evidence of drug interactions. Ann Intern Med 1989;110:606–611.

    PubMed  CAS  Google Scholar 

  158. Aventis Pharma Inc.. Pentacarinat product monograph. Laval, Canada: 2002.

    Google Scholar 

  159. Youle MS, Clarbour J, Gazzard B, Chanas A. Severe hypocalcemia in AIDS patients treated with foscarnet and pentamidine [letter]. Lancet 1988;1:1455–1456.

    PubMed  CAS  Google Scholar 

  160. Collaborative AZT Study Group. Tolerance of AZT in association with trimethoprimsulfamethoxazole, pyrimethamine, or rifampin [abstract]. Fourth International Conference on AIDS, Stockholm, June 12–16, 1988.

    Google Scholar 

  161. Glaxo SmithKline. Daraprim (pyrimethamine) prescribing information. Research Triangle Park, NC, March 2003.

    Google Scholar 

  162. Lee BL, Tuber MG, Chambers HR, Gambertoglio J, Delahunty T. The effect of trimethoprim on the pharmacokinetics of zalcitabine in HIV-infected patients [abstract]. Thirty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17–20, 1995.

    Google Scholar 

  163. Squibb. Fungizone intravenous product monograph. Montreal, Canada, 1996.

    Google Scholar 

  164. Kerr B, Yuen G, Daniels R, Quart B, Anderson R. Strategic approach to nelfinavir mesylate (NFV) drug interactions involving CYP3A metabolism. Fourth National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1997.

    Google Scholar 

  165. Bristol-Myers Squibb Co. Reyataz (atazanavir) prescribing information. Princeton, NJ, June 2003.

    Google Scholar 

  166. Trapnell CB, Narang PK, Li R, Lavelle JP. Increased plasma rifabutin levels with concomitant fluconazole therapy in HIV-infected patients. Ann Intern Med 1996;124:573–576.

    PubMed  CAS  Google Scholar 

  167. Trapnell CB, Lavelle JP, O’Leary CR, et al. Rifabutin does not alter fluconazole pharmacokinetics [abstract PII-106]. Clin Pharmacol Ther 1993;52:196.

    Google Scholar 

  168. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12(suppl 3):S327–S333.

    PubMed  CAS  Google Scholar 

  169. Coker RJ, Tomlinson DR, Parkin J, Harris JRW, Pinching AJ. Interaction between fluconazole and rifampicin [letter]. BMJ 1990;301:818.

    PubMed  CAS  Google Scholar 

  170. Apseloff G, Hilligoss DM, Gardner MJ, et al. Induction of fluconazole metabolism by rifampin: in vivo study in humans. J Clin Pharmacol 1991;31:358–361.

    PubMed  CAS  Google Scholar 

  171. Smith JA, Hardin TC, Patterson TF, Rinaldi MG, Graybill JR. Rifabutin decreases itraconazole plasma levels in patients with HIV infection. Second National Conference on Human Retroviruses and Related Infections, Washington, DC, January 29–February 2, 1995. Abstract 126.

    Google Scholar 

  172. Lefort A, Launay O, Carbon C. Uveitis associated with rifabutin prophylaxis and itraconazole therapy [letter]. Ann Intern Med 1996;125:939–940.

    PubMed  CAS  Google Scholar 

  173. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole [letter]. Clin Infect Dis 1994;18:266.

    PubMed  CAS  Google Scholar 

  174. Polk RE, Crouch M, Israel DS, et al. Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy 1999;19:1378–1384.

    PubMed  CAS  Google Scholar 

  175. Glaxo SmithKline. Agenerase (amprenavir) prescribing information. Research Triangle Park, NC, October 2002.

    Google Scholar 

  176. Lelawongs P, Barone JA, Colaizzi JL, et al. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm 1988;7:228–235.

    PubMed  CAS  Google Scholar 

  177. Pilheu JA, Galati MR, Yunis AS, et al. Interaccion farmacocinetica entre ketconazol, isoniacida y rifampicina [Pharmacokinetic interaction of ketoconazole, isoniazid, and rifampicin]. Medicina 1989;49:43–47.

    PubMed  CAS  Google Scholar 

  178. Kerr B, Lee C, Yuen G, et al. Overview of in-vitro and in-vivo drug interaction studies of nelfinavir mesylate, a new HIV-1 protease inhibitor. Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 22–26, 1997. Abstract 373.

    Google Scholar 

  179. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165–174.

    PubMed  CAS  Google Scholar 

  180. Engelhard D, Stutman HR, Marks MI. Interaction of ketoconazole with rifampin and isoniazid. N Engl J Med 1984;311:1681–1683.

    PubMed  CAS  Google Scholar 

  181. Hoffmann-La Roche. Invirase (saquinavir) prescribing information. Nutley, NJ, July 2002.

    Google Scholar 

  182. Agouron Pharmaceuticals. Viracept (nelfinavir) prescribing information. La Jolla, CA, August 2003.

    Google Scholar 

  183. Chave JP, Munafo A, Chatton JY, Dayer P, Glauser MP, Biollaz J. Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. Antimicrob Agents Chemother 1992;36:1013–1018.

    PubMed  CAS  Google Scholar 

  184. Sadler BM, Gillotin C, Chittick GE, Symonds WT. Pharmacokinetic drug interactions with amprenavir. Twelfth World AIDS Conference, Geneva, Switzerland, June 28–July 3, 1998. Abstract 12389.

    Google Scholar 

  185. Benedek IH, Joshi A, Fiske WD, et al. Pharmacokinetic interaction studies in healthy volunteers with efavirenz and the macrolide antibiotics, azithromycin and clarithromycin. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5, 1998. Abstract 347.

    Google Scholar 

  186. Robinson P, Gigliotti M, Lamson M, Azzam S, MacGregor T. Effect of the reverse transcriptase inhibitor, nevirapine, on the steady-state pharmacokinetics of clarithromycin in HIV-positive patients. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31–February 4, 1999. Abstract 374.

    Google Scholar 

  187. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171:747–750.

    PubMed  Google Scholar 

  188. Ouellet D, Hsu H, Mukherjee D, Locke C, Leonard JM. Assessment of the pharmacokinetic interaction between ritonavir and clarithromycin [Abstract PI-58]. Clin Pharmacol Ther 1996;59:143..

    Google Scholar 

  189. Buss N. Saquinavir soft gel capsule (Fortovase): pharmacokinetics and drug interactions. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1–5, 1998. Abstract 354.

    Google Scholar 

  190. Pastore A, Van Cleef G, Risher EJ, Gillum JG, LeBel M, Polk RE. Dideoxycytidine pharmacokinetics and interaction with clarithromycin in patients seropositive for HIV [abstract]. Fourth National Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 1997.

    Google Scholar 

  191. Polis MA, Piscitelli SC, Vogel S, et al. Clarithromycin lowers plasma zidovudine levels in persons with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997;41:1709–1714.

    PubMed  CAS  Google Scholar 

  192. Rana KZ, Darnowski JW, Strayer AH, Dudley MN. Clarithromycin does not affect phosphorylation of zidovudine in vitro. Antimicrob Agents Chemother 1996;40:1945–1947.

    PubMed  CAS  Google Scholar 

  193. Hurwitz A, Scholzman DL. Effects of antacids on gastrointestinal absorption of isoniazid in rat and man. Am Rev Resp Dis 1974;109:41–47.

    PubMed  CAS  Google Scholar 

  194. Gallicano K, Sahai J, Zaror-Behrens G, Pakuts A. Effect of antacids in didanosine tablet on bioavailability of isoniazid. Antimicrob Agents Chemother 1994;38:894–897.

    PubMed  CAS  Google Scholar 

  195. Sarma GR, Kailasam S, Nair NGK, Narayana ASL, Tripathy SP. Effect of prednisone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid. Antimicrob Agents Chemother 1980;18:661–666.

    PubMed  CAS  Google Scholar 

  196. Lee BL, Tauber MG, Chambers HF, Gambertoglio J, Delahunty T. The effect of zalcitabine on the pharmacokinetics of isoniazid in HIV-infected patients. Thirty-fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 4–7, 1994, p. 3. Abstract A4.

    Google Scholar 

  197. Polk RE, Brophy DF, Israel DS, et al. Pharmacokinetic interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 2001;45:502–508.

    PubMed  CAS  Google Scholar 

  198. Agarwala S, Mummaneni V, Randall D, Geraldes M, Stoltz R, O’Mara E. Pharmacokinetic effect of rifabutin on atazanavir with and without ritonavir in healthy subjects. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24–28, 2002, p. 221. Abstract 445-W.

    Google Scholar 

  199. Sahai J, Narang PK, Hawley-Foss N, Li RC, Kamal M, Cameron DW. A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1995;9:274–279.

    PubMed  CAS  Google Scholar 

  200. Benedek IH, Fiske WD, White SJ, Stevenson D, Joseph JL, Kornhauser DM. Pharmacokinetic interaction between multiple doses of efavirenz and rifabutin in healthy volunteers [abstract]. Clin Infect Dis 1998;27:1008.

    Google Scholar 

  201. Kerr BM, Daniels R, Clendeninn N. Pharmacokinetic interaction of nelfinavir with halfdose rifabutin. Eighth Annual Canadian Conference on HIV/AIDS Research, Victoria, British Columbia, Canada, May 1–4, 1999. Abstract B203.

    Google Scholar 

  202. Sahai J, Stewart F, Swick L, et al. Rifabutin reduces saquinavir plasma levels in HIVinfected patients. Thirty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 1996. Abstract A027.

    Google Scholar 

  203. Benedek IH, Joshi A, Fiske WD, et al. Pharmacokinetic interaction between efavirenz and rifampin in healthy volunteers. Twelfth World AIDS Conference, Geneva, Switzerland, June 28–July 3, 1998. Abstract 42280.

    Google Scholar 

  204. Gallicano KD, Sahai J, Shukla VK, et al. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br J Clin Pharmacol 1999;48:168–179.

    PubMed  CAS  Google Scholar 

  205. Gallant JE, Moore RD, Keruly J, Richman DD, Chaisson RE. Lack of association between acyclovir use and survival in patients with advanced human immunodeficiency virus disease treated with zidovudine. Zidovudine Epidemiology Study Group. J Infect Dis 1995;172:346–352.

    PubMed  CAS  Google Scholar 

  206. Stein DS, Graham NM, Park LP, et al. The effect of the interaction of acyclovir with zidovudine on progression to AIDS and survival. Analysis of data in the Multicenter AIDS Cohort Study. Ann Intern Med 1994;121:100–108.

    PubMed  CAS  Google Scholar 

  207. Cooper DA, Pehrson PO, Pedersen C, et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind randomized trial. European-Australian Collaborative Group. AIDS 1993;7:197–207.

    PubMed  CAS  Google Scholar 

  208. Pedersen C, Cooper DA, Brun-Vezinet F, et al. The effect of treatment with zidovudine with or without acyclovir on HIV p24 antigenaemia in patients with AIDS or AIDSrelated complex. AIDS 1992;6:821–825.

    PubMed  CAS  Google Scholar 

  209. Cooper DA, Pedersen C, Aiuti F, et al. The efficacy and safety of zidovudine with or without acyclovir in the treatment of patients with AIDS-related complex. The European-Australian Collaborative Group. AIDS 1991;5:933–943.

    PubMed  CAS  Google Scholar 

  210. Tartaglione TA, Collier AC, Opheim K, Gianola FG, Benedetti J, Corey L. Pharmacokinetic evaluations of low-and high-dose zidovudine plus high-dose acyclovir in patients with symptomatic human immunodeficiency virus infection. Antimicrob Agents Chemother 1991;35:2225–2231.

    PubMed  CAS  Google Scholar 

  211. Bach MC. Possible drug interaction during therapy with azidothymidine and acyclovir for AIDS [letter]. N Engl J Med 1987;317:547.

    Google Scholar 

  212. Laskin OL, de Miranda P, King DH, et al. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob Agents Chemother 1982;21:804–807.

    PubMed  CAS  Google Scholar 

  213. Reines ED, Gross PA. Antiviral agents. Med Clin North Am 1988;72:691–715.

    PubMed  CAS  Google Scholar 

  214. Gilead Sciences. Vistide product monograph. Foster City, CA, 1996.

    Google Scholar 

  215. Massarella JW, Nazareno LA, Passe S, Min B. The effect of probenecid on the pharmacyokinetics of zalcitabine in HIV-positive patients. Pharm Res 1996;13:449–452.

    PubMed  CAS  Google Scholar 

  216. Freitas VR, Fraser-Smith EB, Matthews TR. Efficacy of ganciclovir in combination with other antimicrobial agents against cytomegalovirus in vitro and in vivo. Antiviral Res 1993;20:1–12.

    PubMed  CAS  Google Scholar 

  217. Faulds D, Heel RC. Ganciclovir-a review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections. Drugs 1990;39:597–638.

    PubMed  CAS  Google Scholar 

  218. Aweeka FT, Brody SR, Jacobson M, Botwin K, Martin-Munley S. Is there a pharmacokinetic interaction between foscarnet and zalcitabine during concomitant administration? Clin Ther 1998;20:232–243.

    PubMed  CAS  Google Scholar 

  219. Koshida R, Vrang L, Gilljam G, Harmenberg J, Oberg B, Wahren B. Inhibition of human immunodeficiency virus in vitro by combinations of 3’-azido-3’-deoxythymidine and foscarnet. Antimicrob Agents Chemother 1989;33:778–780.

    PubMed  CAS  Google Scholar 

  220. Eriksson BF, Schinazi RF. Combinations of 3’-azido-3’-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Antimicrob Agents Chemother 1989;33:663–669.

    PubMed  CAS  Google Scholar 

  221. Aweeka FT, Gambertoglio JG, van der Horst C, Raasch R, Jacobson MA. Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). Antimicrob Agents Chemother 1992;36:1773–1778.

    PubMed  CAS  Google Scholar 

  222. Butt AA. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Reader 2003;13:344–348.

    PubMed  Google Scholar 

  223. Vogt MW, Hartshorn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376–1379.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Pharmacy, University of Toronto, Toronto

    Alice Tseng PharmD, FCSHP (Assistant Professor)

  2. HIV Clinical Pharmacist, Immunodeficiency Clinic, Toronto General Hospital, Toronto, Ontario, Canada

    Alice Tseng PharmD, FCSHP (Assistant Professor)

Authors
  1. Alice Tseng PharmD, FCSHP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Discovery Medicine-Antivirals, GlaxoSmithKline, Research Triangle Park, NC

    Stephen C. Piscitelli PharmD (Director) (Director)

  2. College of Pharmacy and Medicine, University of Illinois at Chicago, Chicago, IL

    Keith A. Rodvold PharmD (Professor of Pharmacy Practice and Associate Professor of Medicine in Pharmacy) (Professor of Pharmacy Practice and Associate Professor of Medicine in Pharmacy)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Tseng, A. (2005). Drugs for HIV-Related Opportunistic Infections. In: Piscitelli, S.C., Rodvold, K.A. (eds) Drug Interactions in Infectious Diseases. Infectious Disease. Humana Press. https://doi.org/10.1385/1-59259-924-9:137

Download citation

  • DOI: https://doi.org/10.1385/1-59259-924-9:137

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-455-5

  • Online ISBN: 978-1-59259-924-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation